Coya Therapeutics Secures Fast Track Designation for ALS Drug, Expands Trial Population
Event summary
- FDA granted Fast Track Designation to COYA 302 for ALS treatment on May 11, 2026.
- ALSTARS trial protocol amended to broaden patient population, increasing enrollment potential.
- $11.1 million private placement led by Dr. Reddy’s Laboratories and Greenlight Capital.
- Cash position stands at $50.7 million as of March 31, 2026.
- Phase 2a study for frontotemporal dementia (FTD) planned for 2H 2026.
The big picture
Coya Therapeutics is advancing its pipeline with strategic regulatory wins and expanded trial access, positioning itself in the competitive landscape of neurodegenerative disease treatments. The Fast Track Designation and broader patient eligibility for COYA 302 reflect growing validation of its Treg-focused approach, while the recent funding bolsters its ability to execute on multiple clinical fronts. The company’s focus on ALS and FTD aligns with increasing industry emphasis on immune modulation for neurodegenerative conditions.
What we're watching
- Regulatory Momentum
- Whether the Fast Track Designation will accelerate COYA 302’s path to market and reduce development timelines.
- Trial Execution
- The pace at which the amended ALSTARS protocol will boost enrollment and impact topline data readout in 1Q 2027.
- Financial Runway
- How the $11.1 million private placement will extend Coya’s cash runway and support multiple clinical programs.
Related topics